Allogeneic CD19-targeted CAR-T therapy (BRL-301) for relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).

BRL-301 - BRL Medicine

etoposide IV - Generic mfg.

cyclophosphamide - Generic mfg.

fludarabine IV - Generic mfg.

Actemra IV (tocilizumab) - Roche, JW Pharma

https://www.asco.org/abstracts-presentations/257977/

YongXian Hu; Qian Tan; Mingming Zhang; Guoqing Wei; Jiazhen Cui; Binghe Tan; Dali Li; Yu Xiang; Bing Du; Mingyao Liu; He Huang

Apr 21, 2026